This study is in progress, not accepting new patients
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Summary
- Eligibility
- for people ages 12-75 (full criteria)
- Location
- at UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Bruce Wang (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Bruce Wang (ucsf)
My lab studies how the different cell types in the liver, in particular the hepatocyte, are generated during development, patterned and maintained during adulthood, and regenerate after injury. Our long-term goals are to improve the understanding of liver disease pathophysiology and develop novel methods of treatment for liver diseases, including cell replacement therapy.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Tanabe Pharma America, Inc.
- ID
- NCT05005975
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 286 people participating
- Last Updated